{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:34:59Z","timestamp":1791167699637,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":975,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000226","name":"Ontario Ministry of Health and Long-Term Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004726","name":"Ministry of Health, British Columbia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013451","name":"European Society for Dermatological Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1038\/jid.2012.387","type":"journal-article","created":{"date-parts":[[2012,10,25]],"date-time":"2012-10-25T08:28:59Z","timestamp":1351153739000},"page":"907-912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study"],"prefix":"10.1016","volume":"133","author":[{"given":"Raed O.","family":"Alhusayen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Juurlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad M.","family":"Mamdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Shear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin R.","family":"Dormuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/jid.2012.387_bb0010","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1038\/ajg.2009.417","article-title":"Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study","volume":"104","author":"Bernstein","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1038\/jid.2012.387_bb0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.sder.2008.07.002","article-title":"Preventing and managing the side effects of isotretinoin","volume":"27","author":"Brelsford","year":"2008","journal-title":"Semin Cutan Med Surg"},{"key":"10.1038\/jid.2012.387_bb0020","first-page":"272","article-title":"Oral isotretinoin: an analysis of its utilization in a managed care organization","volume":"8","author":"Chen","year":"2002","journal-title":"J Manag Care Pharm"},{"key":"10.1038\/jid.2012.387_bb0025","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/ajg.2010.124","article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a case-control study","volume":"105","author":"Crockett","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1038\/jid.2012.387_bb0030","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/S0140-6736(02)11395-X","article-title":"Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases","volume":"360","author":"Dubuquoy","year":"2002","journal-title":"Lancet"},{"key":"10.1038\/jid.2012.387_bb0035","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/gut.2006.093484","article-title":"PPARgamma as a new therapeutic target in inflammatory bowel diseases","volume":"55","author":"Dubuquoy","year":"2006","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1038\/jid.2012.387_bb0040","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.MIB.0000195385.19268.68","article-title":"Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities","volume":"12","author":"Hanauer","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"10.1038\/jid.2012.387_bb0045","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/00128071-200304070-00005","article-title":"Isotretinoin use and subsequent depression and suicide: presenting the evidence","volume":"4","author":"Hull","year":"2003","journal-title":"Am J Clin Dermatol"},{"key":"10.1038\/jid.2012.387_bb0050","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0889-857X(21)00720-1","article-title":"SAPHO syndrome","volume":"18","author":"Kahn","year":"1992","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1038\/jid.2012.387_bb0055","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.4049\/jimmunol.179.6.3724","article-title":"Vitamin A metabolites induce gut-homing FoxP3+ regulatory T cells","volume":"179","author":"Kang","year":"2007","journal-title":"J Immunol"},{"key":"10.1038\/jid.2012.387_bb0060","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2133.1993.tb11849.x","article-title":"Isotretinoin for acne vulgaris--10 years later: a safe and successful treatment","volume":"129","author":"Layton","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2012.387_bb0065","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0025-6196(11)63565-9","article-title":"A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"10.1038\/jid.2012.387_bb0070","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/ajg.2010.303","article-title":"Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease","volume":"105","author":"Margolis","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1038\/jid.2012.387_bb0075","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0140-6736(06)68265-2","article-title":"Defective acute inflammation in Crohn's disease: a clinical investigation","volume":"367","author":"Marks","year":"2006","journal-title":"Lancet"},{"key":"10.1038\/jid.2012.387_bb0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archderm.1985.01660010095028","article-title":"Acne fulminans associated with inflammatory bowel disease. Report of a case","volume":"121","author":"McAuley","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1038\/jid.2012.387_bb0085","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1038\/jid.2012.387_bb0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/1523-1747.ep12580370","article-title":"Isotretinoin produces significant inhibition of monocyte and neutrophil chemotaxis in vivo in patients with cystic acne","volume":"89","author":"Norris","year":"1987","journal-title":"J Invest Dermatol"},{"key":"10.1038\/jid.2012.387_bb0095","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.1572-0241.2006.00632.x","article-title":"Possible association between isotretinoin and inflammatory bowel disease","volume":"101","author":"Reddy","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1038\/jid.2012.387_bb0100","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1345\/aph.10368","article-title":"Isotretinoin-induced inflammatory bowel disease in an adolescent","volume":"35","author":"Reniers","year":"2001","journal-title":"Ann Pharmacother"},{"key":"10.1038\/jid.2012.387_bb0105","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/gut.2008.170530","article-title":"Isotretinoin and intestinal inflammation: what gastroenterologists need to know","volume":"58","author":"Shale","year":"2009","journal-title":"Gut"},{"key":"10.1038\/jid.2012.387_bb0110","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0190-9622(83)70176-3","article-title":"Isotretinoin treatment of acne and related disorders: an update","volume":"9","author":"Shalita","year":"1983","journal-title":"J Am Acad Dermatol"},{"key":"10.1038\/jid.2012.387_bb0115","doi-asserted-by":"crossref","first-page":"c5812","DOI":"10.1136\/bmj.c5812","article-title":"Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study","volume":"341","author":"Sundstrom","year":"2010","journal-title":"BMJ"},{"key":"10.1038\/jid.2012.387_bb0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2133.2009.09430.x","article-title":"Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study","volume":"162","author":"van der Zee","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1038\/jid.2012.387_bb0125","series-title":"Bloomberg News","article-title":"Roche Ordered to Pay $25 Million to Accutane User (Update2)","author":"Voreacos","year":"2010"},{"key":"10.1038\/jid.2012.387_bb0130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000324226","volume":"222","author":"Wakabayashi","year":"2011","journal-title":"Dermatology"},{"key":"10.1038\/jid.2012.387_bb0135","series-title":"Patterns of Health Care in Ontario","first-page":"339","article-title":"A Summary of Studies on the Quality of Health Care Administrative Databases in Canada","author":"Williams","year":"1996"},{"key":"10.1038\/jid.2012.387_bb0140","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1468-3083.2010.03855.x","article-title":"Acne fulminans: explosive systemic form of acne","volume":"25","author":"Zaba","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1038\/jid.2012.387_bb0145","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/sj.jid.5700418","article-title":"Isotretinoin revisited: pluripotent effects on human sebaceous gland cells","volume":"126","author":"Zouboulis","year":"2006","journal-title":"J Invest Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15361728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X15361728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T20:41:33Z","timestamp":1743972093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X15361728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0022202X15361728"],"URL":"https:\/\/doi.org\/10.1038\/jid.2012.387","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isotretinoin Use and the Risk of Inflammatory Bowel Disease: A Population-Based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/jid.2012.387","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Society for Investigative Dermatology, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}